Mikhail V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical
University of St. Petersburg, Russia. Dr. Misha V. Blagosklonny subsequently moved to the USA, where he was
Awarded the prestigious Fogarty Fellowship from the National Institutes of Health.
During his fellowship in Leonard Neckers’ laboratory at the National
Cancer Institute (NCI), he was a co-author of 18 publications on
Various biomedical themes, including targeting
HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last writer for a clinical phase I/II
Trial paper.
 
After authoring seven papers during a brief yet productive
Senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania,
Dr. Blagosklonny returned to NCI to cooperate with Tito Fojo. Together, they
Published 26 papers. Moreover, Dr. Misha Blagosklonny published dozens of experimental research articles and theoretical papers as lead
Writer. The abovementioned sole-author publications
Highlighted two important topics.
The first of those explained selectively killing cancer
Cells with deregulated cell cycle or drug resistance via
Confirming their resistance. The results and underlying
Notion were so revolutionary that they were improperly cited by
Other scientists as “reversal of resistance, ” even though the article was
Titled, “Exploiting of drug resistance instead of its reversal. ” One major
Supporter of this concept was the world-famous scientist Arthur Pardee, with whom Dr.
Blagosklonny co-authored a joint article in 2001.
 
The second topic throughout Dr. Blagosklonny’s sole-author works
Is a research method to produce knowledge by
Uniting a few facts together from seemingly unrelated fields.
This results in new concepts with testable forecasts, which in
Turn can be “tested” by analyzing the literature further. Once again, the
Concept was co-authored by Arthur Pardee in a 2002 article in Nature. The
First success of the new research methodology was the description of the feedback
Regulation of p53, as supported by the discovery of mdm2/p53 loop; and the
Explanation why mutant p53 is always overexpressed, published in 1997. The most
Significant outcome discovered by Dr.
Blagosklonny’s research methods is the hyperfunction (or quasi-programmed)
Theory of aging and the revelation of rapamycin as an exclusively well-tolerated
Anti-aging drug, published in 2006. As mentioned in Scientific American,
Michael Hall, who discovered mTOR in 1991, gives Dr. Blagosklonny recognition for
“connecting dots that others cannot even see. ”
 
In 2002, Dr. Blagosklonny became associate professor of medicine at New York Medical College.
He went on to assume responsibilities as a senior scientist at Ordway
Research Institute in Albany, New York, in 2005, prior to receiving another
Position at Roswell Park Cancer Institute as professor of oncology in 2009.
 
Since coming to Roswell Park Comprehensive Cancer Center in 2009, Dr. Blagosklonny
Has studied the prevention of cancer (an age-related disease) by
Inhibiting organism aging — in other words, “preventing cancer
Via staying young. ” His lab closely worked together with
Andrei Gudkov’s and performed research on the suppression of
Cellular senescence, namely suppression of cellular conversion from healthy quiescence to
Permanent senescence. This led to the discovery of additional anti-aging
Medications beyond rapamycin. The cell culture studies were
Accompanied by studies in mice, including several models such as
Standard and aging mice, p53-deficient mice, and mice on a high-fat diet.
 
Dr. Misha Blagosklonny has also published extensively on the prevention of cellular
Senescence via rapamycin and other mTOR inhibitors, life
Extension and cancer cure in mice, and combinations of anti-
Aging drugs to be appliedamong humans. A
Rapamycin-based combination of seven clinically available medicines has
Been named the “Koschei Formula” and is now used for the treatment of aging in patients
At the Alan Green Clinic in Little Neck, New York.